Fitzgerald Meghan sold $798K of ROIV

Dell (DELL) hit a record $538.47 due to AI demand and S&P 100 inclusion. Roivant (ROIV) surged to $42.50 after positive drug data. Shell (SHEL) reached $95.80 on Gulf of America stake and Morgan Stanley upgrade. Each stock gained 1-18% Tuesday.

Roivant Sciences (ROIV) shares rose 18% after reporting positive Phase 2 results for Mosliciguat, a pulmonary hypertension treatment. The drug showed a 56.3% reduction in pulmonary vascular resistance and a 35.2-meter improvement in six-minute walk distance. Analysts suggest potential $10B annual sales. Success in Phase 3 trials is critical for commercialization and long-term growth.

Dell (DELL), Roivant (ROIV), and Shell (SHEL) hit 52-week highs. Dell rose 1% on AI demand and S&P 100 inclusion, with Q2 AI server revenue near $74B. Roivant gained 18% on positive clinical trial results for mosliciguat. Shell climbed 2% on Gulf of Mexico expansion and a Morgan Stanley upgrade.

Roivant Sciences (ROIV) hit an all-time high after reporting positive results from its PH-ILD treatment trial. The drug, mosliciguat, met primary and secondary endpoints, reducing PVR by 56.3% and improving walking distance. Jefferies raised its price target to $52. Hedge fund holdings surged 41% in Q2.

Bluejay Diagnostics (BJDX) partnered with Lovell Government Services for federal healthcare market access, trading at $1.05, up 27.4%. Pharvaris (PHVS) reported 83% attack rate reduction in HAE study, trading at $37.82, up 7.02%. Roivant (ROIV) showed positive Phase 2 results for mosliciguat, trading at $41.35, up 18.35%. Atara Biotherapeutics (ATRA) updated BLA resubmission plans, trading at $10.71, up 9.73%. PDS Biotech (PDSB) raised $22.55M in PIPE financing, trading at $0.29, up 33.21%.

Roivant Sciences (ROIV) and Pharvaris (PHVS) reached record highs after positive clinical trial results. Roivant's drug, mosliciguat, showed a 56.3% improvement in lung blood flow resistance over 16 weeks. Both companies' stocks surged on the news.